BioSpace News Archive

Cambrian Biopharma, a multi-asset longevity biotech, announced the close of an oversubscribed Series C financing, which raised $100 million.

Catamaran Bio, Inc. today announced the formation of its scientific advisory board (SAB).

Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the issuance of two key US Patents related to its high-performance, exome-wide liquid biopsy platform, NeXT Liquid Biopsy™.

Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today.

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 17 to 0, with 1 abstention, to recommend that the FDA grant Emergency Use Authorization for the companies’ COVID-19 vaccine in children 5 to <12 years of age.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 17 to 0, with 1 abstention, to recommend the FDA grant Emergency Use Authorization (EUA) for the companies’ COVID-19 vaccine in children 5 to <12 years of age.

Mint Pharmaceuticals Inc. is recalling all lots of its prescription losartan tablets, in 50 mg and 100 mg strengths, after tests found an azido impurity -2-butyl-4-chloro-1H imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-yl)-1H tetrazole) above the acceptable limit.

Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced the resignation of Jed A. Latkin as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of the Company, and as a member of the Board of Directors of the Company, effective October 24, 2021.

4D Molecular Therapeutics (Nasdaq: FDMT), announced today that it has commenced an underwritten public offering of 4,500,000 shares of its common stock.